Vanguard Reports 5.57% Stake in Coeptis Therapeutics

Coeptis Therapeutics Holdings Inc reports institutional ownership disclosures.

Rhea-AI Filing Summary

Coeptis Therapeutics Holdings Inc reports institutional ownership disclosures. Vanguard Capital Management reports beneficial ownership of 346,975 shares of Common Stock, representing 5.57% of the class. Vanguard Total Stock Market Index Fund Investor Shares holds 254,749 shares (4.09%). The filing lists voting and dispositive powers and provides Vanguard's Malvern, PA office address.

Insights

Institutional Ownership Analyst

Vanguard reports just-above-5% stake in Coeptis, a typical 13G institutional disclosure.

The filing shows Vanguard Capital Management beneficially owns 346,975 shares (5.57%), with sole dispositive power over that position and sole voting power over 26,244 shares. This is a passive/ownership disclosure under Schedule 13G.

Key dependencies include fund-level holdings and any future amendments if the stake changes above passive thresholds; subsequent 13D/13G amendments will update ownership levels.

Regulatory Compliance Specialist

Schedule 13G format and footnote disclosures align with institutional reporting practices.

The filing includes the SEC Release citation and clarifies affiliates and funds through which Vanguard exercises dispositive power. It identifies the reporting persons and provides signatures dated 05/04/2026.

Material changes to ownership or intent would require amended filings; timing for any amendment is governed by Schedule 13G rules.

Key Figures

Vanguard beneficial ownership: 346,975 shares Percent of class (Vanguard): 5.57% Vanguard Total Stock Market Fund holdings: 254,749 shares +3 more

6 metrics

Vanguard beneficial ownership 346,975 shares Amount beneficially owned reported on Schedule 13G

Percent of class (Vanguard) 5.57% Percent of common stock reported by Vanguard Capital Management

Vanguard Total Stock Market Fund holdings 254,749 shares Holdings by Vanguard Total Stock Market Index Fund Investor Shares

Percent of class (Total Stock Market Fund) 4.09% Percent of common stock for the Total Stock Market Fund

Sole voting power 26,244 shares Shares for which Vanguard reports sole power to vote

Signature date 05/04/2026 Date of filing signatures

Key Terms

beneficially owned, Schedule 13G, sole dispositive power, SEC Release No. 34-39538

4 terms

beneficially owned regulatory

"reflects the securities beneficially owned, or deemed to be beneficially owned"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Schedule 13G regulatory

"Item 1. (a) Name of issuer: Coeptis Therapeutics Holdings Inc"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

sole dispositive power regulatory

"Sole Dispositive Power 346,975.00"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

SEC Release No. 34-39538 regulatory

"In accordance with SEC Release No. 34-39538 (January 12, 1998)"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does Vanguard report in Coeptis Therapeutics (COEP)?

Vanguard Capital Management reports beneficial ownership of 346,975 shares, equal to 5.57% of Coeptis Therapeutics' common stock. The Vanguard Total Stock Market Index Fund Investor Shares holds 254,749 shares (4.09%).

Who filed the Schedule 13G for COEP on behalf of Vanguard?

The filing was made by Vanguard Capital Management and includes holdings managed through affiliated funds. The signatory is Ashley Grim, Head of Global Fund Administration, dated 05/04/2026.

What voting and dispositive powers does Vanguard report for COEP shares?

Vanguard reports sole voting power for 26,244 shares and sole dispositive power for 346,975 shares. Shared voting and dispositive powers are reported as 0.

Does this Schedule 13G indicate Vanguard intends active control over Coeptis?

No. The filing is a passive ownership disclosure under Schedule 13G and does not state any intent to exert control. It lists beneficial ownership and the exercise of dispositive power through Vanguard affiliates.

Where is Vanguard's principal office listed in the COEP filing?

The filing lists Vanguard's principal business office as 100 Vanguard Blvd., Malvern, PA 19355. Coeptis' principal executive office is listed as 105 Bradford Road, Suite 420, Wexford, PA 15090.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/04/2026 - 04:41 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Coeptis Therapeutics Holdings Inc

(Name of Issuer)

Common Stock

(Title of Class of Securities)

19207A207

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 19207A207

1

Names of Reporting Persons

Vanguard Capital Management

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

PENNSYLVANIA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 26,244.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 346,975.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

346,975.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.57 %

12

Type of Reporting Person (See Instructions)

IA

Comment for Type of Reporting Person: In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by Vanguard Capital Management LLC and the following affiliates of Vanguard Capital Management LLC or business divisions of such affiliates: Vanguard Asset Management Limited, Vanguard Fiduciary Trust Company, Vanguard Global Advisers, LLC and Vanguard Investments Australia Ltd. This Schedule 13G includes securities held by Vanguard funds, or sleeves thereof, over which Vanguard Capital Management LLC exercises dispositive power, in addition to securities held by clients over which the affiliates or business divisions of such affiliates indicated above exercise dispositive and/or voting power. This Schedule 13G does not include securities, if any, beneficially owned by other subsidiaries or affiliates of Vanguard Capital Management LLC, or business divisions of such subsidiaries, whose ownership of securities is disaggregated from that of the reporting business unit in accordance with such release.

SCHEDULE 13G

CUSIP Number(s): 19207A207

1

Names of Reporting Persons

Vanguard Total Stock Market Index Fund Investor Shares

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 254,749.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

254,749.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.09 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Coeptis Therapeutics Holdings Inc
(b)	Address of issuer's principal executive offices: 105 Bradford Road, Suite 420, Wexford, PA, 15090
Item 2.
(a)	Name of person filing: Vanguard Capital Management Vanguard Total Stock Market Index Fund Investor Shares
(b)	Address or principal business office or, if none, residence: 100 Vanguard Blvd,, Malvern, PA, 19355
(c)	Citizenship: PA
(d)	Title of class of securities: Common Stock
(e)	CUSIP Number(s): 19207A207
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 346975
(b)	Percent of class: 5.57 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 26244
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 346975
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. Vanguard Capital Management, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.No one other person's interest in the securities reported herein is more than 5%.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Vanguard Capital Management

Signature:	Ashley Grim
Name/Title:	Head of Global Fund Administration
Date:	05/04/2026

Vanguard Total Stock Market Index Fund Investor Shares

Signature:	Ashley Grim
Name/Title:	Head of Global Fund Administration
Date:	05/04/2026